Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, featuring executives Peter Griffith and Murdo Gordon. The presentation will be webcast live and accessible to the public, investors, and media via Amgen's website, with the replay available for 90 days. This event highlights Amgen's ongoing innovation in biotechnology and its broad pipeline targeting diseases like cancer, rare diseases, and heart conditions. Investors can follow updates through Amgen's investor relations channels and social media platforms.
The Schwab U.S. Dividend Equity ETF (SCHD) focuses on 100 stocks with strong dividend histories, offering retirees a reliable income with a 3.27% yield and low fees. However, its top 10 holdings make up 41% of the fund, exposing investors to higher s...
Amgen Inc. has been upgraded to a cautious Buy due to its improved fundamentals, diversified drug pipeline, and attractive risk/reward profile despite recent underperformance against the S&P 500. Key growth drivers include drugs like Imdelltra, Upliz...
Quantinuum, formed by merging Honeywell's quantum division and Cambridge Quantum, debuted on Nasdaq at $68 per share, raising $1.68 billion in an upsized IPO. The company, valued at about $17.6 billion, offers full-stack quantum computing hardware an...
The European Commission has approved Amgen's IMDYLLTRA (tarlatamab) as a monotherapy for adults with advanced small-cell lung cancer (SCLC) after progression on platinum-based chemotherapy. This approval is based on the Phase 3 DeLLphi-304 trial show...
Amgen presented new Phase 3 data at the EULAR 2026 Congress showing that UPLIZNA (inebilizumab) provides sustained disease control and a strong safety profile in IgG4-related disease (IgG4-RD). No flares occurred in patients continuing UPLIZNA, with ...
